Resources from the same session
1057 - TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study
Presenter: Yoshiaki Nakamura
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
4795 - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
Presenter: John Strickler
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
2951 - Impact of clonality and DNA repair mutations on plasma tumor mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
Presenter: Jonathan Loree
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3298 - Early identification of treatment effect by methylated circulating tumor DNA in metastatic colorectal cancer
Presenter: Caroline Thomsen
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5073 - Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer
Presenter: Elisa Fontana
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
2646 - Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first line (1L). PERSEIDA study
Presenter: Manuel Valladares-Ayerbes
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5828 - Pre-operative FOLFOX chemotherapy in advanced colon cancer: pathology analysis of the FOxTROT trial
Presenter: Nick West
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3464 - BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study
Presenter: Niharika Mettu
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3857 - Phase II Study of Pertuzumab and Trastuzumab-emtansine (T-DM1) in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) Trial
Presenter: Andrea Sartore-Bianchi
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5756 - Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): final analysis, tumor biomarkers and methylated ctDNA
Presenter: Filippo Pietrantonio
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract